MAR 2 7 2003 W Please type a plus sign (+) inside this box →

1631.

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number, 10/057.467 **Application Number** Filing Date January 22, 2002 TRANSMITTAL **NOLAN, GARRY F** First Named Inventor **FORM** Group Art Unit 1631 (to be used for all correspondence after initial filing) **Examiner Name** RIGL-005CON Attorney Docket Number Total Number of Pages in This Submission **ENCLOSURES** (check all that apply) Fee Transmittal Form Assignment Papers After Allowance Communication (for an Application) to Group Fee Attached -Drawing(s) Appeal Communication to Board of Appeals and Interferences Amendment / Reply Licensing-related Papers After Final Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Petition Affidavits/declaration(s) Proprietary Information Petition to Convert to a Extension of Time Request Provisional Application Status Letter **Express Abandonment Request** Power of Attorney, Revocation Change of Correspondence Supplemental Information Other Enclosure(s) (please Address identify below): Terminal Disclaimer Disclosure Statement Form PTO/SB/08A 1. Certified Copy of Priority Cited References Request for Refund Documents **Postcard** CD, Number of CD(s Response to Missing Parts/ Incomplete Application Remarks Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Signing Attorney/Agent PAMELA J. SHERWOOD, 36,677 (Reg. No.) **BOZICEVIC, FIELD & FRANCIS LLP** Signature March 21, 2003 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: March 21, 2003 Typed or printed name Susan M. Alessi Signature Date March 21, 2003

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF MAILING rtify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: nmissioner for Patents, Washington, D.C. 20231 on this date. Typed or Printed Name Susan M. Alessi Sum alusi Date March 21, 2003 Signature Attorney Docket **RIGL-005CON** SUPPLEMENTAL First Named Inventor NOLAN, GARRY P. INFORMATION DISCLOSURE STATEMENT **Application Number** 10/057,467 9737 Confirmation No. Filing Date January 22, 2002 Group Art Unit 1631 Address to: Examiner Name Commissioner for Patents Washington, D.C. 20231 "METHODS FOR SCREENING FOR Title: TRANSDOMINANT EFFECTOR PEPTIDES ANI RNA MOLECULES"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

Of the references identified herein that were disclosed in parent application serial number 08/589,109, filed 1/23/1996, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. RIGL-005CON may be charged thereon.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: ___ March 21, 2003_____

Pamela J. Sherwood Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known BAN Substitute for form 1449A/PTO 10/057,467 **Application Number** INFORMATION DISCLOSURE January 22, 2002 Filing Date STATEMENT BY APPLICANT NOLAN, GARRY P. First Named Inventor **Art Unit** 1631 **Examiner Name** (use as many sheets as necessary) RIGL-005CON 3 **Attorney Docket Number** Sheet 1 of

U.S. PATENT DOCUMENTS					
Examiner Initials'	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		4.618.578	10-1986	Burke et al.	
		5.650.489	07-1997	Lam et al.	111
	<u> </u>	5.698,396	12-1997	Pfreundschuh et al.	
		5.747,334	05-1998	Kav et al.	1 5
		5,763.192	06-1998	Kauffman et al.	7 00
		5.770.434	06-1998	Huse	
		5.814.476	09-1998	Kauffman et al.	
		5.817.483	10-1998	Kauffman et al.	3 9 1
		5.824.514	10-1998	Kauffman et al.	
		5.840.479	11-1998	Little et al.	3
		5.935.823	08-1999	Fowlkes et al.	
		5.955.275	09-1999	Kamb et al.	8
		6.194.544	02-2001	Huffman et al.	

•	FOREIGN PATENT DOCUMENTS					
Examiner	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
Initials'		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
		EP 0 440 146 A2	01-1991	Little et al.		
		EP 0 557 897 A1	09-1993	Dillon et al.		
		WO 93/03143 A1	02-1993	Anderson et al.		
		WO 94/18219 A1	08-1994	Barbas et al.		
		WO 94/20608 A1 •	09-1994	Hodgson		
		WO 94/29469 A2	12-1994	Nabel et al.		
		WO 95/11998 A1	05-1995	Wang et al.		
		<u> </u>				

	······································		
Examiner		Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB contra number

Complete if Known stitute for form 1449A/PTO Application Number 10/057,467 INFORMATION DISCLOSURE Filing Date January 22, 2002 STATEMENT BY APPLICANT **First Named Inventor NOLAN, GARRY P Art Unit** 1631 (use as many sheets as necessary) **Examiner Name** 3 **Attorney Docket Number** RIGL-005CON Sheet 2 of OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner T² Initials* No. item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), nublisher city and/or country who ATCC catalog Internet printout regarding Cell Line HB-101 (2001) CWIRLA, S. et al., "Peptides on Phage: A vast library of peptides for identifying ligands" PROC. NATL. ACAD. SCI. USA, Voi. 87, August 1990, pp. 6378-6382. DUBE et al., "Selection of new biologically active molecules from random nucleotide sequences." Gene Vol. 137, Aug 1993, pp. 41-47. DUENAS, M. et al., "Clonal Selection and Amplification of Phage Displayed Antibodies by Linking Antigen Recognition and Phage and Phage Replication", BIO/TECHNOLOGY, Vol. 12, Oct. 1994, pp. 999-1002. FURKA, A. et al., "General method for rapid synthesis of multi-component peptide mixtures", INT. J. PEPTIDE PROTEIN RES., 37, 1991 pp. 487-493. GISSEL, B. et al., "Identification of Avidin and Streptavidin Binding Motifs Among Peptides Selected from a Synthetic Peptide Library Consisting solely of D-Amino Acids", JOURNAL OF PEPTIDE SCIENCE, Vol. 1, 1995, pp. 217-226. GUDKOV et al., "Cloning mammalian genes by expression selection of genetic suppressor elements: Association of kinesin with drug resistance and cell immortalization", (1994), Proc. Natl. Acad. Sci., 91: 3744-3748 HOUGHTEN, R. et al., "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery" NATURE, Vol. 354, 7 Nov. 1991, pp. 84-86. KARTTUNEN et al., Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. PROC. NATL. ACAD. SCI. USA, Vol. 89, 1992, pp. 6020-6024. KAUFFMAN, S. et al., "The NK Model of Rugged Fitness Landscapes And Its Application to Maturation of the Immune Response" J. THEOR. BIOL., Vol. 141(2), 1989, pp. 211-245. KAUFFMAN, S. et al., "Toward a General Theory of Adaptive Walks on Rugged Landscapes", J. THEOR. BIOL. Vol 128(1), 1987, pp. 11-45. LAM, K. et al., "A new type of synthetic peptide library for identifying ligand-binding activity", NATURE Vol. 354, 7 Nov. 1991, pp. 82-84. LONG, E. et al., "Invariant Chain Prevents the HLA-DR Restricted Presentation of a Cytosolic Peptide", THE JOURNAL OF IMMUNOLOGY, 153, 1994, pp. 1487-1494.

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control nur Complete if Known stitute for form 1449A/PTO Application Number 10/057,467 INFORMATION DISCLOSURE Filing Date January 22, 2002 STATEMENT BY APPLICANT First Named Inventor NOLAN, GARRY P. **Art Unit** 1631 **Examiner Name** (use as many sheets as necessary) Sheet 3 **Attorney Docket Number** RIGL-005CON 3 of LUND, A. et al., "Increased cloning efficiency by temperature cycle ligation", NUCLEIC ACIDS RESEARCH, Vol. 24, No. 4, 1996, pp 800-801. MALNATI, M. et al., "Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells", NATURE Vol. 357, 25 June 1992, pp. 702-704. MILLER, A.D. et al., "Improved Retroviral Vectors for Gene Transfer and Expression", BioTechniques, Vol. 7, No. 9, 1989, pp. 980-990. MURPHY, A. et al., "pJzd39: A new type of cDNA expression vector for low background, high efficiency directional cloning", NUCLEIC ACIDS RESEARCH, Vol. 19, No. 12, (1991), pp. 3403-3408. RAYNOR et al., "A Simple and Efficient Procedure for Generating Stable Expression Libraries by cDNA Cloning in a Retroviral Vector", (1994), Mol. Cell. Biol., 14(2): 880-887 ROITT et al., "Kurzes Lehrbuch der Immunologie, 2. Auflage, p. 86, (1991) ROMPP et al., "Bd. 5 P1-S-1995, Georg Thieme Verlag Stuttgart, p. 3543 (in German) SCHUMACHER, T et al., "Synthetic peptide libraries in the determination of T cell epitopes and peptide binding specificity of class I molecules", EUR. J. IMMUNOL. (Germany), Vol. 22 (6), June 1992, pp. 1405-12. SCOTT, J., "Discovering peptide ligands using epitope libraries", TIBS 17, (1992), pp. 241-245. SEED, B. et al., "Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure", PROC. NATL. ACAD. SCI. USA, Vol. 84, May 1987, pp. 3365-3369. STRYER et al., "Biochemie, Heidelberg, Berlin: Spektrum-Verlag, (1994), pp. 53-57 (in German)(published in America in Stryer, (1998), L. Biochemistry 3rd Ed., New York: W.H. Freeman and Company, pp. 50-55 STRYER et al., "Biochemie, Heidelberg, Berlin: Spektrum-Verlag, (1994), pp. 124-126 (in German)(published in America in Stryer, (1998), L. Biochemistry 3rd Ed., New York: W.H. Freeman and Company, pp. 120-123 STRYER et al., "Biochemie, Heidelberg, Berlin: Spektrum-Verlag, (1994), pp. 807-808 (in German)(published in America in Stryer, (1988), L. Biochemistry 3rd Ed., New York: W.H. Freeman and Company, pp. 773-775

Examiner	Date	
Signature	Considered	

Natl. Acad. Sci., 89: 9410-9414

WHITEWAY et al., "Dominant negative selection of heterologous genes: Isolation of Candida albicans genes that interfere with Saccharomyces cerevisiae mating factor-induced cell cycle arrest", (1992), Proc.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.